The IPO filing comes days after the U.K. startup acquired licenses to make and sell Stryker medical devices.
Xeltis scored €45 million for its restorative, bioresorbable, polymer-based heart valve replacement technology.
The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results…
Cardinal Health's $1.2 billion deal to offload its Cardinal Health China unit includes pharma and medical products distribution businesses.
Syapse picked up $30 million in series D financing, funds it will use to scale its oncology precision medicine software.
The approval clears Otsuka to start selling a sensor-enabled version of its schizophrenia drug Abilify designed to improve compliance.
The FDA cleared Cianna Medical’s breast tumor localization system, the first device of its kind to be FDA-cleared for long-term use.
Nexstim won FDA clearance for its noninvasive brain stimulation system that treats major depressive disorder.
SGS pulled the CE Certificate of Conformity over the weekend in response to nonconformity to medical device quality management system standards.
Aspect Imaging earned a CE mark for it neonatal MRI device, which reduces the risks to premature babies who need imaging.
The FDA has approved Stryker’s stent system that, along with neurovascular embolic coils, treats multiple types of aneurysms.